Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc has demonstrated significant investment in its research and development efforts, with R&D expenses increasing to $52.4 million, indicating a commitment to expanding its clinical pipeline and responsiveness to market demands. The successful enrollment of 555 subjects in the SOL-R trial, coupled with robust statistical power, suggests a strong potential for favorable outcomes that could enhance patient retention and overall market share for its durable therapies. Additionally, the FDA's granting of a Special Protocol Assessment for the AXPAXLI program reflects regulatory confidence in the company's innovation and its strategies to address unmet needs in ophthalmic diseases.

Bears say

Ocular Therapeutix Inc. reported net revenue of $14.5 million for the quarter, representing a decline from $15.4 million in the same period the previous year, highlighting a downward trend in sales. The company has consistently incurred significant losses since its inception, which raises concerns regarding its long-term financial sustainability. Furthermore, market competition from existing and emerging therapies poses a substantial risk to Ocular's market penetration and pricing, while potential delays in clinical development and commercialization may exacerbate its financial challenges.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.